Business Medical Dialogues
    • facebook
    • twitter
    Sign in Signup
    • facebook
    • twitter
    Sign in Signup
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    Sign InRegister
    Business Medical Dialogues
    Sign inRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Sun Pharma to ramp up...

    Sun Pharma to ramp up global speciality business; eyes "low-to-mid teens" growth in revenues for FY20

    Medical Dialogues BureauBy Medical Dialogues BureauPublished On 2019-08-01T10:00:36+05:30  |  Updated On 2021-08-16T16:37:19+05:30

    The company is targeting key ailments like psoriasis to gradually ramp up its global speciality business, Dilip Shanghvi said adding that Sun Pharma would continue to invest in branding and promotion of its various speciality products.


    New Delhi: Drug major Sun Pharmaceutical Industries is gradually ramping up its speciality business across global markets as it aims to clock "low-to-mid teens" growth in consolidated revenues in the current fiscal.


    Addressing shareholders in the company's annual report for 2018-19, Sun Pharma Managing Director Dilip Shanghvi said the company is focused at growing each of its business verticals faster than the market in which it operates.


    "Our consistent focus is on growing each of our businesses faster than the market in which they operate. Our global speciality initiatives will supplement this objective as an additional growth engine," Shanghvi said.


    The company is targeting key ailments like psoriasis to gradually ramp up its global speciality business, he said adding that Sun Pharma would continue to invest in branding and promotion of its various speciality products.


    Besides, R&D investments for funding clinical trials of some of the speciality products are also likely to continue in the future, Shanghvi noted.


    On the business outlook for the current fiscal, he said: "For 2019-20, we expect our consolidated revenues to grow by low-to-mid teens, while R&D investments are estimated at 8-9 per cent of sales."


    Read Also: Sun Pharma unveils Ezallor Sprinkle capsules for treating lipid disorder in US


    The Mumbai-based drug firm had reported consolidated revenue from operations at Rs 28,686.28 crore for the fiscal year ended March 2019.


    Shanghvi said the company would also continue to invest in the generics business with a focus on developing differentiated complex products and building a product pipeline across markets.


    "Our strong positioning in the global generics space will ensure that we remain an important player in the generics industry," he added.


    Shanghvi said the company will also continue to focus on optimizing its costs, given the tough phase that the global generics industry is passing through.


    "We strive to optimally utilize our resources with greater involvement of people to make the company more efficient," he added.


    Read Also: Sun Pharma Research Arm- SPARC gets USFDA orphan drug designation for novel kinase inhibitor

    Dilip Shanghvi FY20 pharma pharma company pharma news Psoriasis RnD investment Sun Pharma sun pharma generic business sun pharma latest news Sun Pharma revenue sun pharma speciality business Sun Pharmaceutical Industries 
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      Johnson & Johnson Risperdal Lawsuit: US Court Slashes USD 8 Billion Verdict

      Johnson & Johnson Risperdal Lawsuit: US Court Slashes USD 8 Billion Verdict

      Covid-19 Impact: NPPA asks drugmakers to submit availablility data of 58 APIs, details

      Covid-19 Impact: NPPA asks drugmakers to submit availablility data of 58 APIs, details

      Delhi HC directs cashless service to all hospitals: GIPSA stayed on Ophthalmological Society petition

      Delhi HC directs cashless service to all hospitals: GIPSA stayed on Ophthalmological Society...

      Rising prices of hydroxychloroquine raw material forces small scale pharmas in Haridwar to stop production

      Rising prices of hydroxychloroquine raw material forces small scale pharmas in Haridwar to stop...

      Pharmaceuticals safe in PET packaging: High-level committee

      Pharmaceuticals safe in PET packaging: High-level committee

      Union Pharma Secretary Holds video conference with Pharma manufacturers and associations, takes feedback

      Union Pharma Secretary Holds video conference with Pharma manufacturers and associations, takes...

      NPPA fixes prices of 29 formulations under DPCO, check out details

      NPPA fixes prices of 29 formulations under DPCO, check out details

      Top priority on Delivery of Medicines through Speed Post: Minister

      Top priority on Delivery of Medicines through Speed Post: Minister

      View All

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 29 March 2022 11:15 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier

      This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
      verify here.

      Search only trustworthy HONcode health websites:

      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok
      X
      X